docetaxel anhydrous has been researched along with Febrile Neutropenia in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (55.77) | 24.3611 |
| 2020's | 23 (44.23) | 2.80 |
| Authors | Studies |
|---|---|
| Gilbar, PJ; Hurvitz, SA; Van Belle, H; Wildiers, H | 1 |
| Je, NK; Ku, M | 1 |
| Aggarwal, R; Carneiro, BA; de Kouchkovsky, I; Fong, L; Friedlander, T; Lewis, C; Paris, PL; Phone, A; Rao, A; Ryan, CJ; Small, EJ; Szmulewitz, RZ; Zhang, L | 1 |
| Aruga, T; Doihara, H; Hara, Y; Ishida, T; Kaneko, K; Ohtake, T; Saji, S; Taira, T; Takeshita, T; Tsurutani, J; Tsuyuki, S; Uehara, K; Yamaguchi, Y; Yamashita, T; Yanagita, Y | 1 |
| Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T | 1 |
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
| Chan, LL; Kwok, CCH; Tse, SLA; Wang, F; Wong, MCS; Wong, SPY; Wong, WH | 1 |
| Kawasaki, K; Nara, K; Sato, Y; Seto, Y; Suzuki, H; Takada, T; Toriumi, T; Yagi, K; Yamamoto, T | 1 |
| Ikeda, M; Kataoka, Y; Nakagoshi, H; Suwa, H; Taji, T | 1 |
| Eto, K; Kurogochi, T; Matsumoto, A; Nakayoshi, T; Nyumura, Y; Okamoto, T; Tanishima, Y; Yano, F | 1 |
| Kanji, S; Peltekian, S; Sajwani, S; Wang, X | 1 |
| Blayney, DW; Cummings Joyner, AK; Huang, L; Jarvis, J; Kuderer, NM; Lyman, GH; Monhanlal, R; Nunag, D; Wells, J | 1 |
| Iwata, T; Yamamoto, A | 1 |
| Chan, SK; Chin, CHY; Chong, G; Kwan, MW; Lee, CF; Lee, SF; Leung, K; Ma, VYM; Ng, TY; So, KH; Tang, W; Tsang, HT; Wong, CS; Wong, LKM; Yeung, A; Yip, YTE; Young, WM; Zhou, K | 1 |
| Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S | 1 |
| Hashida, T; Hosohata, K; Hosomi, S; Ikesue, H; Maegawa, N; Mori, Y; Muroi, N; Nakamura, T; Sato, Y; Takano, A; Tomii, K; Uchida, M; Yamaguchi, Y | 1 |
| Hase, T; Hasegawa, Y; Hashimoto, N; Koyama, J; Matsui, A; Matsuzawa, R; Morise, M; Ozone, S; Sato, M; Tanaka, I | 1 |
| Bhat, G; Chawla, S; Cobb, PW; Hasal, SJ; Láng, I; Mezei, K; Moon, YW; Schwartzberg, LS | 1 |
| Emi, A; Kadoya, T; Kimura, Y; Masumoto, N; Okada, M; Sasada, S | 1 |
| Ito, T; Iwasaki, A; Nohara, Y; Ono, S; Tanaka, M; Yamashita, S; Yoshinaga, Y | 1 |
| Chan, K; Chan, TW; Johnson, D; Lee, KC; Ng, B; Ng, J; Poon, DMC; Siu, S | 1 |
| Awan, A; Basulaiman, B; Clemons, M; Fergusson, D; Hiller, JP; Hilton, JF; Hutton, B; Ibrahim, MFK; Joy, AA; Mackey, J; Meza-Junco, J; Ng, T; Nixon, NA; Pitre, L; Pond, G; Saunders, D; Sienkiewicz, M; Thavorn, K; Vandermeer, L; Zhu, X | 1 |
| Du, Q; Li, H; Liu, H; Ye, X; Yu, B; Zhai, Q; Zhang, J; Zhang, Z | 1 |
| Abdel Rahman, H; Abdelghany, EM; Ahmad, I; Allithy, A; Dada, R; Deibas, MY; Farag, K; Ibrahim, RB; Kamel, MK; Nawaz, A; Rasool, H; Zekri, J | 1 |
| Becker, G; Gourieux, B; Levêque, D | 1 |
| Alhasso, A; Carruthers, R; Cascales, A; Dodds, D; Glen, H; Jones, RJ; Lamb, C; Laskey, J; MacLeod, N; Marashi, H; McKay, S; Neilson, S; Rulach, RJ; Russell, JM; Sadoyze, A; Sidek, N; Venugopal, B; Wallace, J; White, L | 1 |
| Alcácera, MA; Andrés, R; Frutos Pérez-Surio, A; Puértolas, I; Salvador, MDT | 1 |
| Fukutomi, A; Hamauchi, S; Kawahira, M; Kawai, S; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y | 1 |
| Hata, A; Katakami, N; Mitsudomi, T; Nakagawa, K; Shimokawa, M; Yamamoto, N | 1 |
| Clemons, M; Dudani, S; Fergusson, D; Fernandes, R; Gyawali, B; Hutton, B; Ibrahim, MFK; Majeed, H; Mazzarello, S; Perdrizet, K; Shorr, R; Stober, C; Vandermeer, L | 1 |
| Kagamu, H; Kaira, K; Kobayashi, K; Mouri, A; Murayama, Y; Shiono, A; Yamaguchi, O | 1 |
| Bernadach, M; Biau, J; Dillies, AF; Durando, X; Kwiatkowski, F; Lapeyre, M; Miroir, J; Moreau, J; Pham-Dang, N; Saroul, N | 1 |
| Ohkura, Y; Udagawa, H; Ueno, M | 1 |
| Crawford, J; Dale, DC; Lyman, GH; Tomita, D; Whittaker, S | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Azuma, K; Hoshino, T; Mizoguchi, Y; Naito, Y; Okayama, Y; Takeoka, H; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S | 1 |
| Abi Gerges, D; Buyse, M; Fung, H; Gelmon, KA; Gorbunova, V; Hegg, R; Ibrahim, A; Konecny, GE; Krasnozhon, D; Lipatov, O; Mackey, JR; Manikhas, A; Martin, M; McCarthy, N; Ramos-Vazquez, M; Semiglazov, V; Simms, L; Thireau, F; Verma, S; Webster, M | 1 |
| Florendo, J; Higgins, B; Jones, G; Kano, J; Leung, M; Marr-Del Monte, T; Menon, T; Myers, R | 1 |
| Briscoe, K; Jain, A; Linsell, J | 1 |
| Chan, KK; Lee, EK; Trudeau, ME; Wong, WW | 1 |
| Aizawa, M; Matsuki, A; Migita, K; Nashimoto, A; Yabusaki, H | 1 |
| André, R; Brito, M; Esteves, S; Isidoro, M; Moreira, A | 1 |
| Hanamoto, A; Honma, K; Inohara, H; Kitamura, K; Morii, E; Nakahara, S; Takenaka, Y; Yamamoto, Y; Yasui, T | 1 |
| Bhat, R; Chen, H; Do, T; Medhekar, R; Niravath, P; Trivedi, MV | 1 |
| Brito, M; Cardoso, C; Miguel, I; Moreira, A; Sousa, M; Winckler, P | 1 |
| Ajani, JA; Assadourian, S; Bahleda, R; Baker, J; Boelle, E; Deutsch, E; Gadgeel, SM; Garris, JL; Izzedine, H; Khan, A; Massard, C; Rogers, JE; Soria, JC | 1 |
| Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Dawoud, R; Faqeer, NA; Hanoun, E; Mashni, O; Nazer, L; Rumman, A | 1 |
| Denkert, C; Eiermann, W; Furlanetto, J; Lederer, B; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Reimer, T; Reinisch, M; Schmatloch, S; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Arnaout, A; Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Joy, AA; Mazzarello, S; Robinson, A; Vandermeer, L | 1 |
| Clemons, M; Dudani, S; Fergusson, D; Fernandes, R; Hutton, B; Ibrahim, MF; Majeed, H; Mazzarello, S; Perdrizet, K; Shorr, R; Stober, C; Vandermeer, L | 1 |
5 review(s) available for docetaxel anhydrous and Febrile Neutropenia
| Article | Year |
|---|---|
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans | 2021 |
Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Humans; Risk Factors; Treatment Outcome | 2018 |
[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Colitis; Docetaxel; Fatal Outcome; Febrile Neutropenia; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Nasopharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Staphylococcal Infections; Taxoids | 2015 |
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Staging; Odds Ratio; Pre-Exposure Prophylaxis; Risk; Taxoids | 2015 |
Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Taxoids | 2017 |
14 trial(s) available for docetaxel anhydrous and Febrile Neutropenia
| Article | Year |
|---|---|
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Docetaxel; Febrile Neutropenia; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Purines; Treatment Outcome | 2022 |
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutropenia; Gemcitabine; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Immunoglobulin Fc Fragments; Middle Aged; Neutropenia; Polyethylene Glycols | 2020 |
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans | 2021 |
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hospitals, University; Humans; Incidence; Lenograstim; Neoplasm Staging; Pharmacoepidemiology; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Risk Factors; Severity of Illness Index; Spain; Taxoids | 2018 |
Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Japan; Lung Neoplasms; Male; Polyethylene Glycols; Ramucirumab; Treatment Outcome | 2018 |
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Polyethylene Glycols; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2019 |
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multivariate Analysis; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids | 2013 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Feasibility Studies; Febrile Neutropenia; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Taxoids | 2014 |
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Fatigue; Febrile Neutropenia; Female; Hand-Foot Syndrome; Humans; Hypertension; Immunoglobulin G; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ramucirumab; Stomatitis; Taxoids; Treatment Outcome | 2015 |
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients.
Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Cisplatin; Docetaxel; Endpoint Determination; Esophageal Neoplasms; Febrile Neutropenia; Feces; Female; Fluorouracil; Gastrointestinal Microbiome; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Neoadjuvant Therapy; Patient Compliance; Propionates; Prospective Studies; Serum Albumin; Synbiotics; Taxoids; Young Adult | 2017 |
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Surface Area; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Humans; Lymphatic Metastasis; Obesity; Taxoids | 2016 |
33 other study(ies) available for docetaxel anhydrous and Febrile Neutropenia
| Article | Year |
|---|---|
Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Retrospective Studies | 2022 |
Evaluation of a novel medical device for pegfilgrastim administration.
Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Recombinant Proteins | 2022 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort s
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; East Asian People; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Retrospective Studies | 2022 |
Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Female; Fluorouracil; Humans; Male; Retrospective Studies | 2023 |
Half Dose Pegfilgrastim for Patients With Breast Cancer During Chemotherapy: A Case-series.
Topics: Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Humans | 2023 |
Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Retrospective Studies | 2023 |
Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Topics: Adult; Docetaxel; Febrile Neutropenia; Humans; Incidence; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy.
Topics: Aged; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Medicare; Retrospective Studies; United States | 2023 |
[Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Ramucirumab; Recombinant Proteins; Retrospective Studies | 2019 |
Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Middle Aged; Retrospective Studies | 2020 |
Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Febrile Neutropenia; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vocal Cord Paralysis | 2020 |
Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors | 2020 |
Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Retrospective Studies | 2020 |
Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Risk Factors | 2021 |
[Comparison of the Incidence of Febrile Neutropenia in Doxorubicin/Cyclophosphamide(AC)and Docetaxel/Cyclophosphamide(TC) Perioperative Chemotherapies for Primary Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Retrospective Studies | 2020 |
Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
Topics: Adult; Aged; Aged, 80 and over; China; Cohort Studies; Docetaxel; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2021 |
Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Prospective Studies; Retrospective Studies | 2021 |
Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Retrospective Studies | 2022 |
[Generic drugs controversy in oncology].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Compounding; Drugs, Generic; Enterocolitis; Febrile Neutropenia; Female; Humans; Legislation, Drug; Medical Oncology; Taxoids; United States | 2017 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Febrile Neutropenia; Gonadotropin-Releasing Hormone; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2018 |
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Japan; Male; Middle Aged; Neoplasms; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Pre-Exposure Prophylaxis; Ramucirumab; Recombinant Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Enteral Nutrition; Febrile Neutropenia; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infections; Male; Middle Aged; Nutritional Status; Retrospective Studies; Thrombocytopenia; Tumor Burden; Weight Loss | 2019 |
Feasibility re-evaluation of 75 mg/m² docetaxel in Japanese patients with previously treated non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Febrile Neutropenia; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Patient Selection; Retreatment; Taxoids; Treatment Outcome | 2014 |
A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Cost of Illness; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Myalgia; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Taxoids | 2015 |
Neutropenic fever rates with adjuvant docetaxel and cyclophosphamide in early breast cancer: audit from regional cancer centre in New South Wales.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Audit; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Humans; New South Wales; Retrospective Studies; Taxoids | 2014 |
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Premedication; Quality-Adjusted Life Years; Taxoids | 2015 |
Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Combinations; Febrile Neutropenia; Female; Gastrectomy; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids | 2016 |
Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hospitalization; Humans; Middle Aged; Neoplasm Staging; Portugal; Retrospective Studies; Taxoids | 2015 |
Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Critical Care; Docetaxel; Drugs, Generic; Febrile Neutropenia; Female; Hospital Mortality; Hospitalization; Humans; Incidence; Middle Aged; Retrospective Studies; Taxoids | 2017 |
Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Humans; Randomized Controlled Trials as Topic; Standard of Care; Taxoids | 2016 |